country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-184333

Copy Link Print Information

SGK1-IN-10

SGK1-IN-10 is an ATP-competitive SGK1 inhibitor with an IC₅₀ of 2.53 μM against human SGK1, and it exhibits blood-brain barrier permeability. SGK1-IN-10 downregulates the phosphorylation levels of MDM2 and GSK-3β, induces apoptosis and inhibits cell migration. SGK1-IN-10 can be used in the research of prostate cancer.

For research use only. We do not sell to patients.

Formula: C₂₄H₂₇F₃N₄O
Molecular Weight:444.49

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

SGK1-IN-10 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

SGK1

2.53 μM (IC₅₀)

All SGK Isoforms :

In Vitro

Anti-cancerApoptosisCell Cycle RegulationEMT / MetastasisOthers

Anti-cancer

SGK1-IN-10 (compound 7h) inhibits proliferation of PC3 prostate cancer cells with an IC₅₀ of 1.08 μM and LNCaP prostate cancer cells with an IC₅₀ of 1.24 μM^[1].

Anti-cancer

SGK1-IN-10 inhibits proliferation of HepG2 liver cancer cells with an IC₅₀ of 1.21 μM and shows low cytotoxicity to LX2 normal liver cells with an IC₅₀ of 10.07 μM, yielding a selectivity index of 9.15^[1].

Anti-cancer

Apoptosis

SGK1-IN-10 (0.5-2.0 μM; 48 h) induces concentration-dependent apoptosis in PC3 prostate cancer cells, with a total apoptotic rate of 74.70% at 2.0 μM^[1].

Anti-cancer

Cell Cycle Regulation

SGK1-IN-10 (0.5-2.0 μM; 48 h) induces concentration-dependent S-phase cell cycle arrest in PC3 prostate cancer cells, with 61.48% of cells in S-phase at 2.0 μM^[1].

Anti-cancer

EMT / Metastasis

SGK1-IN-10 (0.5-2.0 μM; 24-48 h) inhibits migration of PC3 prostate cancer cells in a dose- and time-dependent manner^[1].

Others

SGK1-IN-10 (0.01-10 μM; 2 h) directly binds to and stabilizes SGK1 protein in PC3 prostate cancer cells in a temperature- and concentration-dependent manner^[1].

Anti-cancer

SGK1-IN-10 (0.5-2.0 μM) dose-dependently inhibits phosphorylation of SGK1 substrates MDM2 and GSK-3β in PC3 prostate cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

PC3 prostate cancer cells
Concentration:

0.5 μM, 1.0 μM, 2.0 μM
Incubation Time:

48 h
Result:

Increased total apoptotic rate to 19.64% at 0.5 μM compared to 5.97% in DMSO control.
Increased total apoptotic rate to 28.19% at 1.0 μM compared to 5.97% in DMSO control.
Increased total apoptotic rate to 74.70% at 2.0 μM compared to 5.97% in DMSO control.

Cell Cycle Analysis^[1]

Cell Line:

PC3 prostate cancer cells
Concentration:

0.5 μM, 1.0 μM, 2.0 μM
Incubation Time:

48 h
Result:

Increased S-phase population to 49.59% at 0.5 μM compared to 22.60% in DMSO control.
Increased S-phase population to 59.40% at 1.0 μM compared to 22.60% in DMSO control.
Increased S-phase population to 61.48% at 2.0 μM compared to 22.60% in DMSO control.

Cell Migration Assay^[1]

Cell Line:

PC3 prostate cancer cells
Concentration:

0.5 μM, 1.0 μM, 2.0 μM
Incubation Time:

24 h, 48 h
Result:

Inhibited wound closure in a dose- and time-dependent manner.
Showed significant inhibition at all concentrations at 24 h compared to DMSO control.
Showed significant inhibition at all concentrations at 48 h compared to DMSO control.

Related Protocols :

Chemical Information

Molecular Weight 444.49
Formula C₂₄H₂₇F₃N₄O
SMILES

FC(C1=CC(NC2=CC=C(CN3C[C@H](C)N[C@H](C)C3)C=C2)=NC4=CC=C(OC)C=C14)(F)F
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Zhou Y, et al. Structure-optimized 4-trifluoromethylquinoline derivatives: Dual enhancement of SGK1 inhibition and anti-prostate cancer efficacy. Bioorganic chemistry. 2026 May 28;180:110032. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

SGK1-IN-10

All SGK Isoforms

Biological Activity

Description

IC50 & Target

In Vitro

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

SGK1-IN-10 Related Classifications

HY-184333 Related Classifications

Bioz

Keywords

Your Recently Viewed Products

IC₅₀ & Target